MDxHealth acquires Oncotype DX prostate test from Exact Sciences
MDxHealth SA has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences (NASDAQ:EXAS) as well as the latter's urology sales and marketing team. Under the deal, MDxHealth (MDXH) paid $25M in cash, plus another $5M worth of American Depository Shares. Exact Sciences (EXAS) can also receive up to an additional $70M based on revenue milestones in fiscal years 2023 through 2025. MDxHealth is financing the acquisition through a $35M loan with an affiliate of Innovatus Capital Partners. An additional $35 million can be drawn from Innovatus through a $20M term B loan and a $15 million term C loan in, respectively, 2024 and 2025. After Tuesday's closing bell, Exact Sciences' (EXAS) Q2 2022 results beat on the top and bottom lines though the company lowered its full-year guidance.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
